ストックスクリーナーアプリを入手
13.62
12.66%
1.53
プレマーケット:
13.62
前日終値:
$12.09
開ける：
$13.16
24時間の取引高:
6.97M
Relative Volume:
2.97
時価総額：
$2.05B
収益：
-
当期純損益:
$-647.68M
株価収益率:
-2.4021
EPS:
-5.67
ネットキャッシュフロー:
$-594.49M
1週間 パフォーマンス:
+23.04%
1か月 パフォーマンス:
+55.48%
6か月 パフォーマンス:
+25.30%
1年 パフォーマンス:
-6.46%
1日の値動き範囲:
$12.97
$13.97
1週間の範囲:
$10.95
$13.97
52週間の値動き範囲:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.62 | 1.83B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-06 | 開始されました | Goldman | Buy |
| 2026-01-21 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-06 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 開始されました | Citigroup | Buy |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-09-16 | 開始されました | Jefferies | Buy |
| 2024-09-04 | 開始されました | Bernstein | Outperform |
| 2024-07-24 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2023-12-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-01-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-04 | 開始されました | JP Morgan | Overweight |
| 2022-12-02 | 開始されました | BTIG Research | Buy |
| 2022-10-26 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 開始されました | Piper Sandler | Overweight |
| 2022-08-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-05-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-10 | ダウングレード | UBS | Buy → Neutral |
| 2021-08-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-03-11 | 開始されました | UBS | Buy |
| 2020-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-17 | 開始されました | Cowen | Outperform |
| 2020-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2019-11-22 | 開始されました | Wedbush | Outperform |
| 2019-06-25 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-05-06 | 開始されました | Goldman | Buy |
| 2019-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 繰り返されました | Needham | Buy |
| 2018-07-03 | 繰り返されました | Needham | Buy |
| 2018-07-02 | 繰り返されました | Needham | Buy |
| 2018-04-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-03 | 繰り返されました | Needham | Buy |
すべてを表示
Biohaven Ltd (BHVN) 最新ニュース
(BHVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Biohaven (BHVN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
How Biohaven’s Precision Immunology Pipeline Updates Will Impact Biohaven (BHVN) Investors - simplywall.st
Biohaven | DEF 14A: Definitive information statements - Moomoo
Biohaven Ltd (BSP:BHVN34) Stock PDF (Updated: 2026/06/15) - GuruFocus
A Look At Biohaven (BHVN) Valuation After Fresh Pipeline Updates For BHV 8100 BHV 1300 And BHV 1400 - simplywall.st
Is Biohaven (BHVN) Quietly Reframing Its Investment Story Around Brain Energy and Precision Immunology? - Yahoo Finance
Biohaven (BHVN) Valuation Check After New R&D Milestones In Immunology Neuroscience And Metabolic Programs - Yahoo Finance
Biohaven Pharmaceutical Holding Company Ltd (BHVN) News, Articles, Events & Latest Updates - Stocktwits
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%? - Yahoo Finance
Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)? - Sahm
How (BHVN) Movements Inform Risk Allocation Models - Stock Traders Daily
Biohaven (BHVN) Tops Valuation Grades Among Small-Cap Healthcare Stocks - GuruFocus
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Biohaven Starts First Human Trial of BHV-8100 for Neurological, Retinal and Inflammatory Diseases - marketscreener.com
Biohaven begins first human trial of brain-penetrant drug BHV-8100 - StreetInsider
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PR Newswire
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY) - The Globe and Mail
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Goldman Sachs Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
William Blair Maintains Biohaven(BHVN.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Biohaven’s Opakalim Shows Strong Seizure Control and Superior Tolerability in Epilepsy Clinical Trials - Minichart
Biohaven Ltd. (BHVN) Shares Slide 6.7%—Pressing Key Support at $10.00getLinesFromResByArray error: size == 0 - The League of Women Voters of Texas
Biohaven Showcases Promising Opakalim Epilepsy Data at R&D Day - TipRanks
Biohaven reports strong opakalim seizure control and MoDE/TRAP biomarker wins ahead of pivotal trials - TradingView
Biohaven (BHVN) unveils epilepsy, Graves’ and IgA nephropathy data at 2026 R&D Day - Stock Titan
BiohavenDespite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
Biohaven (BHVN) reports positive Phase 1b autoimmune data - grafa.com
Biohaven stock jumps on positive drug trial results By Investing.com - Investing.com South Africa
Biohaven stock jumps on positive drug trial results - Investing.com
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data - Investing.com Australia
Biohaven reports positive trial data for autoimmune therapies - Investing.com UK
Biohaven reports positive trial data for autoimmune therapies By Investing.com - Investing.com Australia
Biohaven reports positive patient data for autoimmune disease drugs - StreetInsider
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy - PR Newswire
Biohaven (BHVN) Is Up 20.0% After Promising Opakalim Epilepsy Data Release Has The Bull Case Changed? - simplywall.st
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Biohaven opakalim trial shows strong seizure control - grafa.com
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - The AI Journal
Biohaven reports opakalim epilepsy trial data ahead of R&D day By Investing.com - Investing.com Australia
Biohaven Ltd (BHVN) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):